Evaluation of Typical Antipsychotic Augmentation with citalopram in reduction of Negative Symptoms in Inpatient schizophrenia in Ahvaz Golestan Hospital 1389
This study is conducted to evaluate negative symptoms reduction of schizophrenia in inpatients on typical antipsychotic augmentation with citalopram in Ahvaz Golestan Hospital 1389. This study is a randomized double blind clinical trial conducted on 40 patients with schizophrenia, meeting the eligibility criteria. The patients will be randomly assigned to receive either citalopram (20 mg for first week and 40 mg for the next weeks) or placebo. Depression is rule out by Hamilton depression rating scale. PANSS is used to assess negative and positive symptoms at the baseline and 3rd and 6th weeks.
General information
Acronym
IRCT registration information
IRCT registration number:IRCT138902113843N1
Registration date:2010-12-01, 1389/09/10
Registration timing:registered_while_recruiting
Last update:
Update count:0
Registration date
2010-12-01, 1389/09/10
Registrant information
Name
Niloufar Khajeddin
Name of organization / entity
Ahvaz Jundishapor University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 61 1374 3038
Email address
khajeddin@ajums.ac.ir
Recruitment status
Recruitment complete
Funding source
Ahvaz Jundishapur University of Medical Sciences
Expected recruitment start date
2010-08-23, 1389/06/01
Expected recruitment end date
2011-02-20, 1389/12/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluation of Typical Antipsychotic Augmentation with citalopram in reduction of Negative Symptoms in Inpatient schizophrenia in Ahvaz Golestan Hospital 1389
Public title
Negative symptom treatment in schizophrenia disorder
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria: Diagnosis of schizophrenia based on DSM-IV TR structured clinical interview by a psychiatrist (faculty member and psychiatry resident), prominent negative Symptoms (PANSS negative score more than 15) , total PANSS score more than 50, no liver disease, no treatment with ECT within 6 months, age between 18 and 70, illness duration at least 1 year.
Exclusion criteria: depressive disorder based on DSM-IV TR interview and more than 17 score by Hamilton depression rating scale , MR, schizoaffective, Bipolar disorder, Neurological disorders , severe organic disease for example IHD or CHF, treatment with anti depressants or lithium, deaf mute, substance abuse within 1 month ago (except nicotine and caffeine), use of any other drugs which had interactions with this study, active suicidal or homicidal thoughts, breast feeding or pregnancy, past history of allergy or complications with study medication, EPS, at least 3 months interval with the last dose of long term antipsychotic medication